1. Australia Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Neuroscientific Biopharmaceuticals Ltd.

Neuroscientific Biopharmaceuticals Ltd.

AASX:NSB
0.06
AUD
+0.00
(-3.33%)
-0.01EPS
22.99MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.04
-0.02
-0.07
-0.01
- -
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.05
0.1
0.04
0.03
0.04
0.05
0.04
Tangible Book Value per Share
0.06
0.04
0.1
0.04
0.03
0.03
0.02
0.01
Basic Weighted Avg Shares
72
78
143
143
143
145
147
337
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
Net Income, GAAP
-2
-3
-3
-10
-1
- -
-2
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
5
3
14
5
4
9
7
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
4
15
6
5
5
17
15
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-40.95
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
6.65
- -
- -
Return on Common Equity (%)
- -
-65.87
-34.82
-103.71
-20.93
6.46
-16.65
-29.68

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
27.83%
-11.92%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
-101.33%
154.3%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nathan Smith
Full Time Employees
9
Sector
Health technology
Industry
Biotechnology
Address
216 St Georges Terrace Perth WA Australia 6000
IPO Date
Jun 22, 2018
Website
neuroscientific.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
NeuroScientific Biopharmaceuticals Limited is dedicated to advancing peptide-derived pharmaceutical interventions for various neurodegenerative conditions. The company's primary therapeutic asset, EmtinB, a peptide compound, is currently under development for treating neurodegenerative dementias like Alzheimer's disease, alongside degenerative optic nerve disorders such as glaucoma. Additionally, EmtinB has shown promise in preclinical investigations for multiple sclerosis and renal transplantation. Complementing its peptide portfolio, the company utilizes its proprietary StemSmart technology, focused on mesenchymal stromal cell production, which is being explored for conditions such as fistulising Crohn's disease through a special access program. Established in 2002, this Australian biotechnology firm, headquartered in Cottesloe, conducts preclinical and clinical studies to bring its patented technologies to market.